Targeting CDK in triple-negative breast cancer
A team at the University of California, San Francisco has found a dysregulated MYC pathway that underlies the majority of triple-negative breast cancers-a form of the disease with limited treatment options.1 The researchers also showed that inhibitors of cyclin dependent kinase, a target upon which MYC-upregulated cancers are dependent, could selectively kill the triple-negative cancer cells.
The group is planning a clinical trial of an undisclosed cyclin dependent kinase (CDK) inhibitor.
Triple-negative breast cancers do not express estrogen receptor, progesterone receptor and HER2 (EGFR2; ERBB2; neu). These tumors are thus insensitive to many of the treatments for other breast cancer subtypes, such as hormone ablation and Herceptin trastuzumab, a humanized anti-HER2 mAb marketed by Roche and its Genentech Inc. unit.
Due to the lack of well-defined targets, developing targeted therapies against triple-negative disease has